Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma.

Humans Receptors, Chimeric Antigen / genetics Immunotherapy, Adoptive / adverse effects T-Lymphocytes Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy Lymphoma, B-Cell / etiology
CAR-T cells CRISPR/Cas9 TCRKO large deletions lymphoma off-the-shelf safety

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 04 08 2022
accepted: 22 09 2022
entrez: 24 10 2022
pubmed: 25 10 2022
medline: 26 10 2022
Statut: epublish

Résumé

Autologous T cells expressing the Chimeric Antigen Receptor (CAR) have been approved as advanced therapy medicinal products (ATMPs) against several hematological malignancies. However, the generation of patient-specific CAR-T products delays treatment and precludes standardization. Allogeneic

Identifiants

DOI: 10.3389/fimmu.2022.1011858 PMID: 36275777 PMC: PMC9585383
pubmed: 36275777
doi: 10.3389/fimmu.2022.1011858
pmc: PMC9585383
doi:

Substances chimiques

Receptors, Chimeric Antigen 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1011858

Informations de copyright

Copyright © 2022 Maldonado-Pérez, Tristán-Manzano, Justicia-Lirio, Martínez-Planes, Muñoz, Pavlovic, Cortijo-Gutiérrez, Blanco-Benítez, Castella, Juan, Wenes, Romero, Molina-Estévez, Marañón, Herrera, Benabdellah and Martin.

Déclaration de conflit d'intérêts

Authors MT-M, PJ-L, and CB-B were employed by LentiStem Biotech. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nat Rev Drug Discov. 2020 Mar;19(3):185-199
pubmed: 31900462
Mol Ther. 2022 Oct 5;30(10):3155-3175
pubmed: 35711141
Microbiol Mol Biol Rev. 1999 Jun;63(2):349-404
pubmed: 10357855
Mol Ther. 2016 Aug;24(7):1178-86
pubmed: 27203439
J Clin Invest. 2016 Jun 1;126(6):2123-38
pubmed: 27111235
Mol Ther. 2021 Feb 3;29(2):636-644
pubmed: 33010231
Blood. 2010 May 27;115(21):4293-301
pubmed: 20233969
Mol Ther. 2018 May 2;26(5):1215-1227
pubmed: 29605708
Lancet. 2020 Dec 12;396(10266):1885-1894
pubmed: 33308471
Mol Ther Oncolytics. 2022 May 18;25:335-349
pubmed: 35694446
Cell Metab. 2016 Jan 12;23(1):63-76
pubmed: 26674251
Front Immunol. 2021 Dec 15;12:780145
pubmed: 34975869
Nat Rev Genet. 2014 May;15(5):321-34
pubmed: 24690881
Curr Protoc Bioinformatics. 2009 Mar;Chapter 4:Unit 4.10
pubmed: 19274634
N Engl J Med. 2011 Aug 25;365(8):725-33
pubmed: 21830940
J Exp Med. 2018 Mar 5;215(3):985-997
pubmed: 29436394
Blood. 2020 Sep 17;136(12):1407-1418
pubmed: 32483603
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Lancet. 2015 Feb 7;385(9967):517-528
pubmed: 25319501
Nat Commun. 2022 Feb 2;13(1):627
pubmed: 35110541
Cold Spring Harb Perspect Biol. 2020 Oct 1;12(10):
pubmed: 31932318
Stem Cell Res Ther. 2021 Jul 28;12(1):428
pubmed: 34321099
Bioinformatics. 2017 Jan 15;33(2):286-288
pubmed: 27559154
Nat Biotechnol. 2018 Sep;36(8):765-771
pubmed: 30010673
Nature. 2017 Mar 2;543(7643):113-117
pubmed: 28225754
Mol Ther. 2017 Apr 5;25(4):949-961
pubmed: 28237835
Cell Rep Med. 2021 Dec 21;2(12):100473
pubmed: 35028614
Front Immunol. 2016 Mar 24;7:89
pubmed: 27047489
Int J Cancer. 2020 Dec 15;147(12):3438-3445
pubmed: 32535920
Biol Blood Marrow Transplant. 2016 Apr;22(4):705-709
pubmed: 26772158
Nat Rev Immunol. 2007 May;7(5):340-52
pubmed: 17438575
Exp Hematol. 2022 Jun;110:13-19
pubmed: 35304271
Blood. 2012 Mar 22;119(12):2709-20
pubmed: 22160384
Genome Res. 2002 Apr;12(4):656-64
pubmed: 11932250
Blood. 2014 Jul 31;124(5):822-6
pubmed: 24869942
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Front Immunol. 2021 Oct 06;12:744823
pubmed: 34691052
Front Immunol. 2020 Sep 29;11:570672
pubmed: 33117361
Nat Methods. 2014 Jul;11(7):705-6
pubmed: 24972169
Bone Marrow Transplant. 2022 Feb;57(2):156-159
pubmed: 35046545
J Clin Invest. 2016 Jan;126(1):318-34
pubmed: 26657860
Mol Ther Nucleic Acids. 2020 Sep 4;21:523-526
pubmed: 32711379
Cancer Immunol Immunother. 2018 Jul;67(7):1053-1066
pubmed: 29605883
Leukemia. 2021 Dec;35(12):3581-3584
pubmed: 34145373
Clin Cancer Res. 2017 May 1;23(9):2255-2266
pubmed: 27815355
Blood. 2012 Jun 14;119(24):5697-705
pubmed: 22535661
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Immunity. 2014 Jul 17;41(1):116-26
pubmed: 25035956
Front Immunol. 2021 Dec 01;12:732135
pubmed: 34925314
Cancer Discov. 2013 Apr;3(4):388-98
pubmed: 23550147
Nature. 2018 Aug;560(7717):E8-E9
pubmed: 30089922
Bone Marrow Transplant. 1997 Dec;20(11):945-52
pubmed: 9422473
Mol Cancer. 2022 Mar 18;21(1):78
pubmed: 35303871
Genome Biol. 2021 Aug 20;22(1):236
pubmed: 34416913
Nucleic Acids Res. 2019 Aug 22;47(14):7402-7417
pubmed: 31127293
Front Immunol. 2020 Jun 19;11:1217
pubmed: 32636841
Cancers (Basel). 2021 Apr 16;13(8):
pubmed: 33923528
Nat Rev Mol Cell Biol. 2019 Nov;20(11):698-714
pubmed: 31263220
Clin Cancer Res. 2014 Nov 15;20(22):5708-19
pubmed: 24833662

Auteurs

Noelia Maldonado-Pérez (N)

Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.

María Tristán-Manzano (M)

Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.
LentiStem Biotech, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.

Pedro Justicia-Lirio (P)

Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.
LentiStem Biotech, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.

Elena Martínez-Planes (E)

Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.

Pilar Muñoz (P)

Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.
Department of Celular Biology, Faculty of Sciences, University of Granada, Granada, Spain.

Kristina Pavlovic (K)

Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.
Cellular Therapy Unit, Maimonides Institute of Biomedical Research in Córdoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain.

Marina Cortijo-Gutiérrez (M)

Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.

Carlos Blanco-Benítez (C)

Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.
LentiStem Biotech, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.

María Castella (M)

Department of Hematology, ICMHO, Hospital Clínic de Barcelona, Barcelona, Spain.

Manel Juan (M)

Department of Hematology, ICMHO, Hospital Clínic de Barcelona, Barcelona, Spain.

Mathias Wenes (M)

Department of Oncology, University of Lausanne, Épalinges, Switzerland.

Pedro Romero (P)

Department of Oncology, University of Lausanne, Épalinges, Switzerland.

Francisco J Molina-Estévez (FJ)

Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.

Concepción Marañón (C)

Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.

Concha Herrera (C)

Cellular Therapy Unit, Maimonides Institute of Biomedical Research in Córdoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain.

Karim Benabdellah (K)

Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.

Francisco Martin (F)

Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.
Department of Biochemistry and Molecular Biology III and Immunology, Faculty of Medicine, University of Granada, Granada, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Efficacy and safety of universal (TCRKO)...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Récepteurs cytoplasmiques et nucléaires › Récepteurs chimériques pour l'antigène › Efficacy and safety of universal (TCRKO)...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunisation passive › Transfert adoptif › Immunothérapie adoptive › Efficacy and safety of universal (TCRKO)...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Efficacy and safety of universal (TCRKO)...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Leucémie lymphoïde › Leucémie-lymphome lymphoblastique à précurseurs B et T › Efficacy and safety of universal (TCRKO)...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Lymphome malin non hodgkinien › Lymphome B › Efficacy and safety of universal (TCRKO)...